BACKGROUND: Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. METHODS: We cond...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!